A Biorefinery for a Modern Bioeconomy.
MIMMEA Biorefinery transforms Africa's botanical biodiversity into high-value bioactive compounds — powering the next generation of nutraceuticals, cosmeceuticals, and pharmaceutical inputs.
$120B
Global bioactives market by 2030
5
Product verticals in pipeline
8
UN SDGs directly addressed
10K+
Smallholder farmers in network
Our Mission
"We exist to translate Africa's botanical heritage into the molecules that will define the next century of health, beauty, and nutrition — sustainably, equitably, and at scale."
— MIMMEA Biorefinery Founding Team
Five Verticals
One platform. A portfolio of bioactive futures.
Botanical Extracts
Standardized extracts from indigenous medicinal and aromatic plants for nutraceutical, cosmetic, and pharmaceutical buyers.
Learn more 2ScalingPlant Cell Cultures
Sustainable, traceable production of high-value molecules in controlled bioreactors — independent of harvest seasons.
Learn more 3DifferentiatedGCCE Coffee Actives
Green Coffee Cell Extracts: a proprietary line of antioxidant-rich actives derived from Uganda's coffee biodiversity.
Learn more 4DefensibleEndemic Species IP
A growing portfolio of compounds isolated from East African endemic species — protected under access & benefit-sharing.
Learn more 5FrontierPhytoBiome Lysates
Next-generation skin-microbiome ingredients combining plant cell metabolites with microbial co-cultures.
Learn moreTechnology Platform
Five integrated modules. One end-to-end biorefinery.
From responsibly sourced biomass to standardized, certified bioactives — every stage of the value chain runs on a single, modular platform designed for traceability, throughput, and scientific rigour.
How the platform worksCompetitive Edge
Three structural advantages — built in, not bolted on.
Circular Sourcing
Side-streams from coffee, tea, and spice value chains become inputs — closing loops with smallholder cooperatives.
Modular Bioreactor
A unit-process platform that scales from gram to ton without rebuilding — capital-efficient capacity expansion.
Endemic IP
Exclusive access to African endemic flora under formal benefit-sharing — a moat competitors cannot replicate.
Building Africa's bioeconomy. Looking for partners who think in decades.
We work with strategic investors, mission-aligned LPs, and downstream partners ready to back deep-science platforms.